Many New Oncology Drugs In 2012, With Prices That Test The Limits
Ten thousand dollars per month for new oncology drugs has become just about standard, and the trend is not likely to go away soon. Drug makers in 2012 found pricing in oncology to be inelastic and continue to test the boundaries within which payors – and society – will play.
Candid conversations with C-suite leaders.
More from Leadership
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.